KRAS and neoplasm: In ovarian cancer, ATMIN promotes cisplatin resistance by regulating the DYNLL1-MRN signaling axis [39]; in tongue cancer, ATMIN promotes tumor metastasis by activating KRAS pathway [40], while its role in NPC remains to be investigated.